licensing

News

Roche licenses Innovent ADC that could challenge Amgen drug

Roche licenses rights to a DLL3-targeted ADC from China's Innovent, hoping to bring a competitor to Amgen's lung cancer therapy Imdelltra to market.

News

MSD makes its obesity move with $2bn Hansoh deal

MSD has been rumoured to be considering a takeover of Viking Therapeutics in order to get a horse in the obesity therapy race, but chose instead to back a runner from China's Hansoh Pharma.

News

GSK builds neuro, cancer pipeline with trio of deals

GSK has added to its R&D pipeline via partnerships with Muna Therapeutics, Rgenta Therapeutics, and Duality Biologics.

News

Genmab expands its pipeline with $630m Scancell deal

Genmab has licensed another anti-glycan antibody for cancer from UK biotech Scancell as it continues to expand its in-house pipeline.

News

Gilead looks beyond Trodelvy with Tubulis alliance

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415m.

News

Ipsen doubles up in TCEs for cancer, adding Biomunex drug

Ipsen has expanded its oncology pipeline by licensing a T cell engager (TCE) therapy from Paris-based startup Biomunex for up to $610m.

Roche licenses Innovent ADC that could challenge Amgen drug

MSD makes its obesity move with $2bn Hansoh deal

GSK builds neuro, cancer pipeline with trio of deals

Genmab expands its pipeline with $630m Scancell deal

Gilead looks beyond Trodelvy with Tubulis alliance

Ipsen doubles up in TCEs for cancer, adding Biomunex drug

DNA testing can help right racial imbalance in breast cancer

Using AI-driven synthetic personas to take your insights fur...

licensing

Editor's Picks